VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2021 | LIGHTHOUSE (OP-108): daratumumab monotherapy vs triplet therapy in R/R myeloma

Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, gives an update on the LIGHTHOUSE (OP-108) trial (NCT04649060). This Phase III study is designed to evaluate the efficacy and safety of melflufen plus dexamethasone and daratumumab vs daratumumab alone in patients with relapsed/refractory (R/R) multiple myeloma previously treated with an immunomodulatory drug (IMiD) and a proteasome inhibitor. The primary objective of this trial is to investigate the superiority of progression-free survival (PFS) in patients treated with triplet therapy vs daratumumab alone. Key secondary endpoints include overall response rate (ORR), duration of response and safety. Patient enrolment has begun. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.


Honoraria from lectures and participation in boards from: Janssen, BMS-Celgene, Abbvie, Amgen, Takeda, GSK, Sanofi, Oncopeptides, Pfizer, Regeneron, Adaptive, Roche, Bluebird-bio, Sea-Gen.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter